BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19435908)

  • 1. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.
    Difeo A; Huang F; Sangodkar J; Terzo EA; Leake D; Narla G; Martignetti JA
    Cancer Res; 2009 Jun; 69(11):4733-41. PubMed ID: 19435908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.
    Narla G; DiFeo A; Fernandez Y; Dhanasekaran S; Huang F; Sangodkar J; Hod E; Leake D; Friedman SL; Hall SJ; Chinnaiyan AM; Gerald WL; Rubin MA; Martignetti JA
    J Clin Invest; 2008 Aug; 118(8):2711-21. PubMed ID: 18596922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.
    Sangodkar J; DiFeo A; Feld L; Bromberg R; Schwartz R; Huang F; Terzo EA; Choudhri A; Narla G
    Lung Cancer; 2009 Dec; 66(3):292-7. PubMed ID: 19328586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer.
    Chen H; Chen L; Sun L; Zhen H; Li X; Zhang Q
    Gastric Cancer; 2011 Oct; 14(4):339-52. PubMed ID: 21538018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.
    DiFeo A; Narla G; Hirshfeld J; Camacho-Vanegas O; Narla J; Rose SL; Kalir T; Yao S; Levine A; Birrer MJ; Bonome T; Friedman SL; Buller RE; Martignetti JA
    Clin Cancer Res; 2006 Jun; 12(12):3730-9. PubMed ID: 16778100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.
    DiFeo A; Feld L; Rodriguez E; Wang C; Beer DG; Martignetti JA; Narla G
    Cancer Res; 2008 Feb; 68(4):965-70. PubMed ID: 18250346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of KLF6 and its splice variants in cancer therapy.
    DiFeo A; Martignetti JA; Narla G
    Drug Resist Updat; 2009; 12(1-2):1-7. PubMed ID: 19097929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.
    Hatami R; Sieuwerts AM; Izadmehr S; Yao Z; Qiao RF; Papa L; Look MP; Smid M; Ohlssen J; Levine AC; Germain D; Burstein D; Kirschenbaum A; DiFeo A; Foekens JA; Narla G
    Sci Transl Med; 2013 Jan; 5(169):169ra12. PubMed ID: 23345610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
    Narla G; DiFeo A; Yao S; Banno A; Hod E; Reeves HL; Qiao RF; Camacho-Vanegas O; Levine A; Kirschenbaum A; Chan AM; Friedman SL; Martignetti JA
    Cancer Res; 2005 Jul; 65(13):5761-8. PubMed ID: 15994951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.
    Vetter D; Cohen-Naftaly M; Villanueva A; Lee YA; Kocabayoglu P; Hannivoort R; Narla G; M Llovet J; Thung SN; Friedman SL
    Hepatology; 2012 Oct; 56(4):1361-70. PubMed ID: 22535637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
    Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
    Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.
    Yea S; Narla G; Zhao X; Garg R; Tal-Kremer S; Hod E; Villanueva A; Loke J; Tarocchi M; Akita K; Shirasawa S; Sasazuki T; Martignetti JA; Llovet JM; Friedman SL
    Gastroenterology; 2008 May; 134(5):1521-31. PubMed ID: 18471523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform.
    Liang WC; Wang Y; Xiao LJ; Wang YB; Fu WM; Wang WM; Jiang HQ; Qi W; Wan DC; Zhang JF; Waye MM
    RNA Biol; 2014; 11(7):845-54. PubMed ID: 24921656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function.
    Rodríguez E; Aburjania N; Priedigkeit NM; DiFeo A; Martignetti JA
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury.
    Ghiassi-Nejad Z; Hernandez-Gea V; Woodrell C; Lang UE; Dumic K; Kwong A; Friedman SL
    Hepatology; 2013 Feb; 57(2):786-96. PubMed ID: 22961688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation.
    Lee EF; Czabotar PE; van Delft MF; Michalak EM; Boyle MJ; Willis SN; Puthalakath H; Bouillet P; Colman PM; Huang DC; Fairlie WD
    J Cell Biol; 2008 Jan; 180(2):341-55. PubMed ID: 18209102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.
    DiFeo A; Narla G; Camacho-Vanegas O; Nishio H; Rose SL; Buller RE; Friedman SL; Walsh MJ; Martignetti JA
    Oncogene; 2006 Sep; 25(44):6026-31. PubMed ID: 16702959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions.
    Hanoun N; Bureau C; Diab T; Gayet O; Dusetti N; Selves J; Vinel JP; Buscail L; Cordelier P; Torrisani J
    J Hepatol; 2010 Nov; 53(5):880-8. PubMed ID: 20801538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.
    Huh SJ; Chen YL; Friedman SL; Liao J; Huang HJ; Cavenee WK; Robertson GP
    J Natl Cancer Inst; 2010 Aug; 102(15):1131-47. PubMed ID: 20660366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.